<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142658</url>
  </required_header>
  <id_info>
    <org_study_id>ONX1801.000-C</org_study_id>
    <nct_id>NCT04142658</nct_id>
  </id_info>
  <brief_title>PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on Apixaban</brief_title>
  <official_title>A Prospective, Randomized, Active (Warfarin) Controlled, Parallel-arm Clinical Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely and Effectively on Apixaban</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CryoLife, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Duke Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CryoLife, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, warfarin is the only approved anticoagulation for patients with mechanical valves.
      The purpose of this study is to determine if participants with an On-X Prosthetic Heart Valve
      / On-X aortic valve can be maintained safely and effectively on apixaban. Both the On-X
      aortic valve and apixaban have been approved for use by the US Food and Drug Administration
      (FDA) but they have not been approved to be used together.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an unmet clinical need for an alternative to warfarin, such as a direct oral
      anticoagulant (DOAC), as anticoagulation in participants with an aortic mechanical prosthetic
      valve. Some participants may be genetically hyper- or hypo-responsive to warfarin, which
      makes management difficult. Another small group of participants is allergic to warfarin. A
      much larger group of participants has difficulty maintaining warfarin control due to dietary
      and drug interactions. Finally, the requirement for routine blood testing makes people
      reluctant to take warfarin. All of these factors drive younger participants in need of aortic
      valve replacement (AVR) toward selection of a tissue valve instead of a mechanical valve.
      Despite multiple studies (randomized, matched and risk adjusted) that show that tissue valves
      are associated with worse outcomes, younger participants choose this type of valve to avoid
      warfarin. In addition, multiple clinical studies have shown valve reoperation rates are
      higher for tissue valves used in these younger participants. Providing an alternative to
      warfarin anticoagulation may lead younger participants to choose a mechanical valve with
      greater durability and better clinical outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel control and treatment arm at a 1:1 ratio.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-Primary Efficacy Objective</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if apixaban is non-inferior to warfarin (INR target range 2.0 - 3.0) for patients with an On-X mechanical heart valve implanted in the aortic position for the primary composite outcome of valve thrombosis and valve-related thromboembolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Efficacy Objective</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if apixaban provides acceptable anticoagulation for patients with an On-X mechanical heart valve implanted in the aortic position for the primary composite outcome of valve thrombosis and valve-related thromboembolism compared with an objective performance criterion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of major bleeding events (superiority)</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if apixaban is superior to warfarin (INR target range 2.0 - 3.0) in the safety outcome of major bleeding in patients with an On-X mechanical heart valve implanted in the aortic position.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of valve-related thrombotic events (superiority)</measure>
    <time_frame>2 years</time_frame>
    <description>To determine if apixaban is superior to warfarin (INR target range 2.0 - 3.0) for the primary composite outcome of valve thrombosis and valve-related thromboembolism in patients with an On-X mechanical heart valve implanted in the aortic position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Objective</measure>
    <time_frame>2 years</time_frame>
    <description>To compare apixaban with warfarin (INR target range 2.0 - 3.0) for the individual components of the primary outcome (valve thrombosis and valve-related thromboembolism) in patients with an On-X mechanical heart valve implanted in the aortic position.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Objective</measure>
    <time_frame>2 years</time_frame>
    <description>To compare apixaban with warfarin (INR target range 2.0 - 3.0) for the primary composite outcome of valve thrombosis and valve-related thromboembolism in prespecified subgroups of patients with an On-X mechanical heart valve implanted in the aortic position.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Aortic Valve Failure</condition>
  <arm_group>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 5 mg twice daily(BID) or 2.5 mg BID
For participants randomized to apixaban, INR testing will be performed on the current warfarin dose with the following algorithm to initiate apixaban
INR &lt; 2; stop warfarin and start apixaban
INR 2.0 to 3.0; hold warfarin for 2 days, start apixaban on day 3
INR &gt; 3.0 to 4.0; hold warfarin for 4 days, start apixaban on day 5
INR &gt; 4.0; hold warfarin for 2 days, recheck INR, refer to steps 1, 2, or 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the warfarin arm will continue warfarin in the INR range of (2.0-3.0)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 5 MG</intervention_name>
    <description>For patients that do NOT meet the following criteria
age ≥ 80 years
weight ≤ 60 kilograms
creatinine ≥ 1.5 mg/dL (133 micromol/L)</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban 2.5 MG</intervention_name>
    <description>For patients that meet at least 2 of the following criteria
age ≥ 80 years
weight ≤ 60 kilograms
creatinine ≥ 1.5 mg/dL (133 micromol/L)</description>
    <arm_group_label>Apixaban</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>Active Control Intervention</description>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>On-X Aortic Mechanical Valve</intervention_name>
    <description>Inclusion Criterion: Implantation of an On-X mechanical valve in the aortic position at least 3 months (90 days) ago.</description>
    <arm_group_label>Apixaban</arm_group_label>
    <arm_group_label>Warfarin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age at the time of giving informed consent.

          -  Participants currently receiving warfarin anticoagulation and who are able to receive
             warfarin with a target INR 2.0 to 3.0.

          -  Participants are able to take low-dose aspirin at a dose of 75 -100 mg daily or have a
             documented contraindication to aspirin use.

          -  Implantation of an On-X mechanical valve in the aortic position at least 3 months (90
             days) ago.

          -  Female participants of childbearing potential, including those who are less than 2
             years post-menopausal, must agree to, and comply with using a highly effective method
             of birth control (eg, barrier contraceptives [condom or diaphragm with a spermicidal
             gel], hormonal contraceptives [implants, injectables, combination oral contraceptives,
             transdermal patches, or contraceptive rings], intrauterine devices or sexual
             abstinence) while partaking in this study. In addition, all women of childbearing
             potential must agree to continue to use birth control throughout the study until last
             study visit.

          -  Informed of the full nature and purpose of the study, including possible risks and
             side effects, given ample time and opportunity to read and understand this
             information, and sign and date the written informed consent before inclusion in the
             study.

        Exclusion Criteria:

          -  Mechanical valve in any position other than aortic valve.

          -  Any cardiac surgery in the three months (90 days) prior to enrollment.

          -  Need to be on aspirin &gt;100 mg daily or a P2Y12 inhibitor (clopidogrel, ticagrelor,
             prasugrel, or ticlopidine).

          -  Known hypersensitivity or other contraindication to apixaban.

          -  On dialysis or a creatinine clearance &lt; 25 mL/min.

          -  Ischemic stroke or intracranial hemorrhage within 3 months.

          -  Active pathological bleeding at the time of screening for enrollment.

          -  Active endocarditis at the time of screening for enrollment.

          -  Pregnant, plan to become pregnant, or are breast feeding.

          -  On concomitant combined strong P-gp and CYP3A4 inducers or inhibitors.

          -  History of non-compliance with recommended monthly INR testing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Svensson, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Steering Committee</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Alexander, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Steering Committee</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brittanny Boyer, BS</last_name>
    <phone>1-888-427-9654</phone>
    <email>proactxainfo@cryolife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Mahoney, BS</last_name>
    <email>proactxainfo@cryolife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tucson Medical Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Natalia E Calles</last_name>
      <email>Natalias.EliasCalles@tmcaz.com</email>
    </contact>
    <investigator>
      <last_name>Raj Bose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI St. Vincent Heart Institute</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Bass</last_name>
      <email>lbass@stvincenthealth.com</email>
    </contact>
    <investigator>
      <last_name>Thomas S Rayburn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marx P Genovez, MD</last_name>
      <email>MGenovez@llu.edu</email>
    </contact>
    <investigator>
      <last_name>Anees J Razzouk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Koyano</last_name>
      <email>tkoyano3@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Fischbein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sharp Memorial</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chris Kohlmyer</last_name>
      <email>ckohlmyer@sdcardiac.com</email>
    </contact>
    <investigator>
      <last_name>Karl Limmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Santa Clara</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nancy Mendelssohn</last_name>
      <phone>650-299-4165</phone>
      <email>nancy.d.mendelssohn@kp.org</email>
    </contact>
    <investigator>
      <last_name>Hon Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arben Ademi</last_name>
      <email>Aademi@harthosp.org</email>
    </contact>
    <investigator>
      <last_name>Robert C Hagberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shands Hospital (University of Florida Health)</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Cobb, PhD, CCRP</last_name>
      <email>jessica.cobb@surgery.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Beaver, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Medical Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Joseph, RN, CCRP</last_name>
      <phone>904-308-6405</phone>
      <email>lisa.joseph@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Mark Mostovych, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracey Purvis</last_name>
      <email>tracey.purvis@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Kevin D Accola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tallahassee Memorial Hospital</name>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <zip>32308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Plasay</last_name>
      <email>Rebecca.plasay@tmh.org</email>
    </contact>
    <investigator>
      <last_name>David Saint, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>USF/Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thanh Tran</last_name>
      <email>thanhtran@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>Erol Belli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Indian River Hospital</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Layla Landgraf</last_name>
      <email>layla.landgraf@irmc.cc</email>
    </contact>
    <investigator>
      <last_name>Mark A Malias, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Atlanta Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carolyn Bernstein</last_name>
      <email>caryn.Bernstein@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Vinod Thourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30332</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michelle Fielding</last_name>
      <email>mfield4@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northeast Georgia Medical Center</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Patrick</last_name>
      <email>donna.patrick@nghs.com</email>
    </contact>
    <investigator>
      <last_name>Alan Wolfe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern Memorial</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Huskin</last_name>
      <email>Anna.Huskin@nm.org</email>
    </contact>
    <investigator>
      <last_name>Sukit Malaisrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OSF Cardiovascular Institute</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Hillis</last_name>
      <email>stephanie.j.hillis@osfhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>David G Cable, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health Methodist Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mona Geinosky, RN, MSN, CCRP</last_name>
      <email>mgeinosky@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joel S Corvera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan/ St. Francis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Kioussopous</last_name>
      <email>kathleen.kioussopoulos@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Vijay Rao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betsey Gallant</last_name>
      <email>Bgallant@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Reed Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kate Calligi</last_name>
      <email>kcummi15@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Lawton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Briana Drago</last_name>
      <email>bdrago@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Prem Shekar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Debbie Conroy, RN, BSN</last_name>
      <email>dconboy@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>David Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Majeski</last_name>
      <email>christine.majeski@allina.com</email>
    </contact>
    <contact_backup>
      <last_name>Alyssa Taffe</last_name>
      <email>alyssa.taffe@allina.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Sun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcia Brott</last_name>
      <phone>612-625-1172</phone>
      <email>brott001@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Andrew Shaffer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jolene Erola, MBA</last_name>
      <phone>507-266-9515</phone>
      <email>Erola.jolene@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Alberto Pochettino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane Peterman</last_name>
      <phone>816-932-5989</phone>
      <email>dpeterman@saint-lukes.org</email>
    </contact>
    <investigator>
      <last_name>John R Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marci Damiano</last_name>
      <email>damianom@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Marc Moon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc Haynes, BSN</last_name>
      <phone>314-996-5708</phone>
      <email>mph7052@bjc.org</email>
    </contact>
    <investigator>
      <last_name>James Scharff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Odvody, RN</last_name>
      <email>jessica.odvody@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Aleem Siddique, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morningside Hospital Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stella Palencia</last_name>
      <email>stella.palencia@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>John Puskas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Alonzo</last_name>
      <email>aa2974@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Hiroo Takayama, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NewYork-Presbyterian/ Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathan Palaparthi</last_name>
      <email>ntp2001@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Lau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vassar Brothers Medical Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camile Finkle</last_name>
      <phone>845-473-1188</phone>
      <phone_ext>51210</phone_ext>
      <email>cfinkle1@health-quest.org</email>
    </contact>
    <investigator>
      <last_name>Jason Sperling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gianni Brunet</last_name>
      <phone>585-273-1652</phone>
      <email>gianni_brunet@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Knight, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Beth Hollister</last_name>
      <email>bahollister68@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chad Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Hejl</last_name>
      <email>hejls@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Douglas Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lani Brighton</last_name>
      <email>lani.brighton@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Michael Moront, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Donna Grossman</last_name>
      <email>dgrossman@okheart.com</email>
    </contact>
    <investigator>
      <last_name>Mohammad K Ghani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shobana Ganesan, PhD</last_name>
      <phone>503-494-4192</phone>
      <email>ganesan@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Howard Song, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Hospital Allentown</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deborah Herr, RN, MSN</last_name>
      <phone>610-402-7195</phone>
      <email>Deborah.Herr@lvhn.org</email>
    </contact>
    <investigator>
      <last_name>James Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tristar Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hallie Hank</last_name>
      <email>Hallie.Hank@HCAhealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Seenu Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William P. Clements Jr. University Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Mcneil</last_name>
      <email>sarah.mcneil@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Michael A Wait, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital at Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Megan White, MS</last_name>
      <phone>469-814-4181</phone>
      <email>Megan.white1@BSWHealth.org</email>
    </contact>
    <investigator>
      <last_name>Katherine Harrington, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alyssa Messina</last_name>
      <email>alyssa.messina@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Craig Selzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henrico Doctors' Hospital</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Raymond</last_name>
      <email>jennifer.raymond@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Chiwon Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Roanoke Memorial Hospital</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brook Mitchell</last_name>
      <email>bamitchell@carilionclinic.org</email>
    </contact>
    <investigator>
      <last_name>Mark Joseph, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roslyn Pierce</last_name>
      <email>roslyn.pierce@swedish.org</email>
    </contact>
    <investigator>
      <last_name>Eric Lehr, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miriam Silva</last_name>
      <email>silvacm8@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Gabriel S Aldea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tacoma General Hosital</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janey Barnhart, RN</last_name>
      <email>mbarnhart@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Dennis Nichols, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lekha Nelavelli</last_name>
      <phone>608-262-9383</phone>
      <email>nelavelli@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Nilto De Oliveira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Neumann</last_name>
      <email>enemann@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Paul J Pearson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marg Holland</last_name>
      <email>Marg.Holland@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>William Kent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Haveman, CRCP</last_name>
      <email>khaveman@fraserclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Shahzad Karim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>BC V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Mok, MSc, CCRP, CCRC, MICR</last_name>
      <email>cmok@providencehealth.ba.ca</email>
    </contact>
    <investigator>
      <last_name>Joel Price, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Jubilee Hospital/ Victoria Heart Institute Foundation</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R1B2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angie Munoz</last_name>
      <phone>250-595-1884</phone>
      <email>amunoz@vhip.org</email>
    </contact>
    <investigator>
      <last_name>Michael Perchinsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital- London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Fox, BA, RRT</last_name>
      <email>stephanie.fox@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Michael Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Fortier</last_name>
      <email>JFortier@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>Marc Ruel, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Akins CW, Miller DC, Turina MI, Kouchoukos NT, Blackstone EH, Grunkemeier GL, Takkenberg JJ, David TE, Butchart EG, Adams DH, Shahian DM, Hagl S, Mayer JE, Lytle BW; Councils of the American Association for Thoracic Surgery; Society of Thoracic Surgeons; European Assoication for Cardio-Thoracic Surgery; Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity. Guidelines for reporting mortality and morbidity after cardiac valve interventions. J Thorac Cardiovasc Surg. 2008 Apr;135(4):732-8. doi: 10.1016/j.jtcvs.2007.12.002.</citation>
    <PMID>18374749</PMID>
  </reference>
  <reference>
    <citation>Bourguignon T, Lhommet P, El Khoury R, Candolfi P, Loardi C, Mirza A, Boulanger-Lothion J, Bouquiaux-Stablo-Duncan AL, Marchand M, Aupart M. Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50-65 years. Eur J Cardiothorac Surg. 2016 May;49(5):1462-8. doi: 10.1093/ejcts/ezv384. Epub 2015 Nov 2.</citation>
    <PMID>26530269</PMID>
  </reference>
  <reference>
    <citation>Chambers JB, Pomar JL, Mestres CA, Palatianos GM. Clinical event rates with the On-X bileaflet mechanical heart valve: a multicenter experience with follow-up to 12 years. J Thorac Cardiovasc Surg. 2013 Feb;145(2):420-4. doi: 10.1016/j.jtcvs.2011.12.059. Epub 2012 Feb 17.</citation>
    <PMID>22341654</PMID>
  </reference>
  <reference>
    <citation>Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, Blatchford J, Devenny K, Friedman J, Guiver K, Harper R, Khder Y, Lobmeyer MT, Maas H, Voigt JU, Simoons ML, Van de Werf F; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013 Sep 26;369(13):1206-14. doi: 10.1056/NEJMoa1300615. Epub 2013 Aug 31.</citation>
    <PMID>23991661</PMID>
  </reference>
  <reference>
    <citation>Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Aortic valve replacement with mechanical vs. biological prostheses in patients aged 50-69 years. Eur Heart J. 2016 Sep 7;37(34):2658-67. doi: 10.1093/eurheartj/ehv580. Epub 2015 Nov 11.</citation>
    <PMID>26559386</PMID>
  </reference>
  <reference>
    <citation>Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, Woo YJ. Mechanical or Biologic Prostheses for Aortic-Valve and Mitral-Valve Replacement. N Engl J Med. 2017 Nov 9;377(19):1847-1857. doi: 10.1056/NEJMoa1613792.</citation>
    <PMID>29117490</PMID>
  </reference>
  <reference>
    <citation>Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92. doi: 10.1056/NEJMoa1107039. Epub 2011 Aug 27.</citation>
    <PMID>21870978</PMID>
  </reference>
  <reference>
    <citation>Head SJ, Mylotte D, Mack MJ, Piazza N, van Mieghem NM, Leon MB, Kappetein AP, Holmes DR Jr. Considerations and Recommendations for the Introduction of Objective Performance Criteria for Transcatheter Aortic Heart Valve Device Approval. Circulation. 2016 May 24;133(21):2086-93. doi: 10.1161/CIRCULATIONAHA.115.020493. Review.</citation>
    <PMID>27217434</PMID>
  </reference>
  <reference>
    <citation>Head SJ, Çelik M, Kappetein AP. Mechanical versus bioprosthetic aortic valve replacement. Eur Heart J. 2017 Jul 21;38(28):2183-2191. doi: 10.1093/eurheartj/ehx141. Review.</citation>
    <PMID>28444168</PMID>
  </reference>
  <reference>
    <citation>IntHout J, Ioannidis JP, Borm GF. The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014 Feb 18;14:25. doi: 10.1186/1471-2288-14-25.</citation>
    <PMID>24548571</PMID>
  </reference>
  <reference>
    <citation>Samsa G, Matchar DB, Dolor RJ, Wiklund I, Hedner E, Wygant G, Hauch O, Marple CB, Edwards R. A new instrument for measuring anticoagulation-related quality of life: development and preliminary validation. Health Qual Life Outcomes. 2004 May 6;2:22.</citation>
    <PMID>15132746</PMID>
  </reference>
  <reference>
    <citation>Lester PA, Coleman DM, Diaz JA, Jackson TO, Hawley AE, Mathues AR, Grant BT, Knabb RM, Ramacciotti E, Frost CE, Song Y, Wakefield TW, Myers DD Jr. Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model. Arterioscler Thromb Vasc Biol. 2017 May;37(5):942-948. doi: 10.1161/ATVBAHA.116.308649. Epub 2017 Feb 23.</citation>
    <PMID>28232327</PMID>
  </reference>
  <reference>
    <citation>McNicholas KW, Ivey TD, Metras J, Szentpetery S, Marra SW, Masters RG, Dilling EW, Slaughter MS, Mack MJ. North American multicenter experience with the On-X prosthetic heart valve. J Heart Valve Dis. 2006 Jan;15(1):73-8; discussion 79.</citation>
    <PMID>16480015</PMID>
  </reference>
  <reference>
    <citation>Palatianos GM, Laczkovics AM, Simon P, Pomar JL, Birnbaum DE, Greve HH, Haverich A. Multicentered European study on safety and effectiveness of the On-X prosthetic heart valve: intermediate follow-up. Ann Thorac Surg. 2007 Jan;83(1):40-6.</citation>
    <PMID>17184628</PMID>
  </reference>
  <reference>
    <citation>Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, Fermin L, McGrath M, Kong B, Hughes C, Sethi G, Wait M, Martin T, Graeve A; PROACT Investigators. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014 Apr;147(4):1202-1210; discussion 1210-1. doi: 10.1016/j.jtcvs.2014.01.004. Epub 2014 Jan 12.</citation>
    <PMID>24512654</PMID>
  </reference>
  <reference>
    <citation>Puskas JD, Gerdisch M, Nichols D, Fermin L, Rhenman B, Kapoor D, Copeland J, Quinn R, Hughes GC, Azar H, McGrath M, Wait M, Kong B, Martin T, Douville EC, Meyer S, Ye J, Jamieson WRE, Landvater L, Hagberg R, Trotter T, Armitage J, Askew J, Accola K, Levy P, Duncan D, Yanagawa B, Ely J, Graeve A; PROACT Investigators. Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve Replacement. J Am Coll Cardiol. 2018 Jun 19;71(24):2717-2726. doi: 10.1016/j.jacc.2018.03.535.</citation>
    <PMID>29903344</PMID>
  </reference>
  <reference>
    <citation>Tossios P, Reber D, Oustria M, Holland-Letz T, Germing A, Buchwald D, Laczkovics A. Single-center experience with the On-X prosthetic heart valve between 1996 and 2005. J Heart Valve Dis. 2007 Sep;16(5):551-7.</citation>
    <PMID>17944128</PMID>
  </reference>
  <reference>
    <citation>Williams MA, van Riet S. The On-X heart valve: mid-term results in a poorly anticoagulated population. J Heart Valve Dis. 2006 Jan;15(1):80-6.</citation>
    <PMID>16480016</PMID>
  </reference>
  <reference>
    <citation>Wu Y, Butchart EG, Borer JS, Yoganathan A, Grunkemeier GL. Clinical evaluation of new heart valve prostheses: update of objective performance criteria. Ann Thorac Surg. 2014 Nov;98(5):1865-74. doi: 10.1016/j.athoracsur.2014.05.006. Epub 2014 Sep 23. Review.</citation>
    <PMID>25258160</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 9, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

